The results showed that 1) both treatments can effectively activate CD8+ Teff cells in the peripheral blood, but MTT has a stronger promoting effect on cell anti-tumor immune activity than RFA; 2) MTT treatment activates the PI3K-AKT-mTOR pathway and significantly upregulates the response to interferon stimulation in CD8+ Teff cells; 3) compared with RFA, MTT treatment can more effectively induce CD8+ Teff cells to exert the effect function, which helps both cells to play synergistic roll tumor immunotherapy. This evidence concerns the gene AKT1 and neoplasm.